Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 1
1957 1
1958 2
1961 1
1962 1
1964 3
1965 2
1966 1
1969 1
1970 1
1971 2
1973 1
1974 1
1975 4
1976 2
1977 7
1978 3
1979 2
1980 4
1981 4
1982 1
1983 1
1984 1
1985 4
1987 4
1988 3
1989 1
1990 3
1991 1
1992 6
1994 4
1995 8
1996 9
1997 4
1998 4
1999 10
2000 15
2001 15
2002 15
2003 7
2004 13
2005 9
2006 21
2007 17
2008 19
2009 12
2010 24
2011 28
2012 25
2013 27
2014 36
2015 36
2016 37
2017 42
2018 35
2019 49
2020 57
2021 48
2022 54
2023 47
2024 42
2025 45

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

804 results

Results by year

Filters applied: . Clear all
Page 1
Oncologic emergencies and urgencies: A comprehensive review.
Gould Rothberg BE, Quest TE, Yeung SJ, Pelosof LC, Gerber DE, Seltzer JA, Bischof JJ, Thomas CR Jr, Akhter N, Mamtani M, Stutman RE, Baugh CW, Anantharaman V, Pettit NR, Klotz AD, Gibbs MA, Kyriacou DN. Gould Rothberg BE, et al. Among authors: gerber de. CA Cancer J Clin. 2022 Nov;72(6):570-593. doi: 10.3322/caac.21727. Epub 2022 Jun 2. CA Cancer J Clin. 2022. PMID: 35653456 Free article. Review.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.
Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Brahmer JR, et al. Among authors: gerber de. J Immunother Cancer. 2021 Jun;9(6):e002435. doi: 10.1136/jitc-2021-002435. J Immunother Cancer. 2021. PMID: 34172516 Free PMC article.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Borghaei H, et al. Among authors: gerber de. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27. N Engl J Med. 2015. PMID: 26412456 Free PMC article. Clinical Trial.
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Borghaei H, et al. Among authors: gerber de. J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449799 Free PMC article. Clinical Trial.
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Leal T, Kotecha R, Ramlau R, Zhang L, Milanowski J, Cobo M, Roubec J, Petruzelka L, Havel L, Kalmadi S, Ward J, Andric Z, Berghmans T, Gerber DE, Kloecker G, Panikkar R, Aerts J, Delmonte A, Pless M, Greil R, Rolfo C, Akerley W, Eaton M, Iqbal M, Langer C; LUNAR Study Investigators. Leal T, et al. Among authors: gerber de. Lancet Oncol. 2023 Sep;24(9):1002-1017. doi: 10.1016/S1470-2045(23)00344-3. Lancet Oncol. 2023. PMID: 37657460 Clinical Trial.
Myelination and mTOR.
Figlia G, Gerber D, Suter U. Figlia G, et al. Among authors: gerber d. Glia. 2018 Apr;66(4):693-707. doi: 10.1002/glia.23273. Epub 2017 Dec 6. Glia. 2018. PMID: 29210103 Free PMC article. Review.
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S. De Ruysscher D, et al. Among authors: gerber de. Clin Lung Cancer. 2022 May;23(3):e264-e268. doi: 10.1016/j.cllc.2021.07.005. Epub 2021 Jul 19. Clin Lung Cancer. 2022. PMID: 34489161 Free article. Clinical Trial.
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.
Iyengar P, Zhang-Velten E, Court L, Westover K, Yan Y, Lin MH, Xiong Z, Patel M, Rivera D, Chang J, Saunders M, Shivnani A, Lee A, Hughes R, Gerber D, Dowell J, Gao A, Heinzerling J, Li Y, Ahn C, Choy H, Timmerman R. Iyengar P, et al. Among authors: gerber d. JAMA Oncol. 2021 Oct 1;7(10):1497-1505. doi: 10.1001/jamaoncol.2021.3186. JAMA Oncol. 2021. PMID: 34383006 Free PMC article. Clinical Trial.
Transplant First, Dialysis Last.
Kshirsagar AV, Kibbe MR, Gerber DA. Kshirsagar AV, et al. Among authors: gerber da. JAMA Surg. 2019 Nov 1;154(11):991-992. doi: 10.1001/jamasurg.2019.4286. JAMA Surg. 2019. PMID: 31536117 No abstract available.
804 results